TMCnet

Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™

Initiated Phase 3 trial of avigbagene parvec in adults with Gaucher type 1 ...

ACS At APFE: Showcasing High-Quality PET Plastic Films For A Wide Range Of Applications

FOSHAN, GUANGDONG, CHINA, January 15, 2026 /EINPresswire.com/ -- Foshan AoChuanShun New Material Industrial Co., Ltd.
Nanowerk

Spray-on nanocomposite coating combines antibacterial power with glass-like hardness for touchscreens

A spray-applied nanocomposite coating kills over 99.99% of bacteria on touchscreens while resisting scratches, combining ...

Single enzyme streamlines production of all four RNA building blocks

A single enzyme that can generate all four nucleoside triphosphates, the building blocks of ribonucleic acid (RNA), has been ...
Reuters

US startup Substrate announces chipmaking tool that it says will rival ASML

SAN FRANCISCO, Oct 28 (Reuters) - Substrate, a small U.S. startup, said on Tuesday that it had developed a chipmaking tool capable of competing with the most advanced lithography equipment made by ...
C&EN

Controlling Selectivity in Electrochemical Conversion of Organic Mixtures through Dynamic Control of Electrode Microenvironments

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Organic electrosynthesis using renewable electricity offers a sustainable approach to ...
BioSpace

AceLink Therapeutics Completes 6-Month Primary Phase of AL01211 Clinical Study in Fabry Disease Patients

AL01211, a novel oral GCS inhibitor, shows favorable safety and robust biomarker reduction in Phase 2 trial in Fabry patients NEWARK, Calif.--(BUSINESS WIRE)--AceLink Therapeutics, a clinical-stage ...